Bio-Rad Laboratories Inc. (BIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Bio-Rad Laboratories Inc. (BIO) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (59/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+124.3% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How BIO Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | 51.9% | 1.8% | $759.9M | $374.6M | 0.5% |
| FY 2024 | $2.57B | 53.7% | 10.5% | -$1.84B | $289.6M | 2.9% |
| FY 2023 | $2.67B | 44% | 12.6% | -$637.3M | $254.7M | 7.8% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring BIO)
- ✓Live walkthrough of BIO's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
BIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIO. Explore sector supply chains on /butterfly.
BIO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Bio-Rad Laboratories Inc. (BIO)?
In FY 2025 (10-K), BIO converted $2.6B of revenue into a 51.9% gross margin, 1.8% operating margin, and $374.6M in free cash flow (14.5% FCF margin).